Cargando…

Preclinical Characterization of a Stabilized Gastrin-Releasing Peptide Receptor Antagonist for Targeted Cancer Theranostics

Radiolabeled gastrin-releasing peptide receptor (GRPR) antagonists have shown great promise for the theranostics of prostate cancer; however, their suboptimal metabolic stability leaves room for improvements. It was recently shown that the replacement of Gly(11) with Sar(11) in the peptidic [D-Phe(6...

Descripción completa

Detalles Bibliográficos
Autores principales:	Abouzayed, Ayman, Kanellopoulos, Panagiotis, Gorislav, Alisa, Tolmachev, Vladimir, Maina, Theodosia, Nock, Berthold A., Orlova, Anna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10377574/ https://www.ncbi.nlm.nih.gov/pubmed/37509170 http://dx.doi.org/10.3390/biom13071134

Ejemplares similares

Peptide Radioligands in Cancer Theranostics: Agonists and Antagonists
por: Nock, Berthold A., et al.
Publicado: (2023)

In Vivo Stabilization of a Gastrin-Releasing Peptide Receptor Antagonist Enhances PET Imaging and Radionuclide Therapy of Prostate Cancer in Preclinical Studies
por: Chatalic, Kristell L.S., et al.
Publicado: (2016)

[(111)In]In/[(177)Lu]Lu-AAZTA(5)-LM4 SST(2)R-Antagonists in Cancer Theranostics: From Preclinical Testing to First Patient Results
por: Nock, Berthold A., et al.
Publicado: (2023)

Nonpeptidic Z360-Analogs Tagged with Trivalent Radiometals as Anti-CCK(2)R Cancer Theranostic Agents: A Preclinical Study
por: Nock, Berthold A., et al.
Publicado: (2022)

Synthesis and Preclinical Evaluation of Radio-Iodinated GRPR/PSMA Bispecific Heterodimers for the Theranostics Application in Prostate Cancer
por: Abouzayed, Ayman, et al.
Publicado: (2019)

Preclinical Evaluation of (99m)Tc-Labeled GRPR Antagonists maSSS/SES-PEG(2)-RM26 for Imaging of Prostate Cancer
por: Abouzayed, Ayman, et al.
Publicado: (2021)

Phase I Trial of [(99m)Tc]Tc-maSSS-PEG(2)-RM26, a Bombesin Analogue Antagonistic to Gastrin-Releasing Peptide Receptors (GRPRs), for SPECT Imaging of GRPR Expression in Malignant Tumors
por: Chernov, Vladimir, et al.
Publicado: (2023)

[(68)Ga]Ga-DATA(5m)-LM4, a PET Radiotracer in the Diagnosis of SST(2)R-Positive Tumors: Preclinical and First Clinical Results
por: Kanellopoulos, Panagiotis, et al.
Publicado: (2022)

Optimizing the Profile of [(99m)Tc]Tc–NT(7–13) Tracers in Pancreatic Cancer Models by Means of Protease Inhibitors
por: Kanellopoulos, Panagiotis, et al.
Publicado: (2020)

Toward Stability Enhancement of NTS(1)R-Targeted Radioligands: Structural Interventions on [(99m)Tc]Tc-DT1
por: Kanellopoulos, Panagiotis, et al.
Publicado: (2023)

[(99m)Tc]Tc-DB1 Mimics with Different-Length PEG Spacers: Preclinical Comparison in GRPR-Positive Models
por: Kanellopoulos, Panagiotis, et al.
Publicado: (2020)

Preclinical Evaluation of the GRPR-Targeting Antagonist RM26 Conjugated to the Albumin-Binding Domain for GRPR-Targeting Therapy of Cancer
por: Abouzayed, Ayman, et al.
Publicado: (2020)

[(99m)Tc]Tc-DB15 in GRPR-Targeted Tumor Imaging with SPECT: From Preclinical Evaluation to the First Clinical Outcomes
por: Nock, Berthold A., et al.
Publicado: (2021)

Trastuzumab cotreatment improves survival of mice with PC‐3 prostate cancer xenografts treated with the GRPR antagonist (177)Lu‐DOTAGA‐PEG(2)‐RM26
por: Mitran, Bogdan, et al.
Publicado: (2019)

Evaluation of Tumor-Targeting Properties of an Antagonistic Bombesin Analogue RM26 Conjugated with a Non-Residualizing Radioiodine Label Comparison with a Radiometal-Labelled Counterpart
por: Oroujeni, Maryam, et al.
Publicado: (2019)

Side-Chain Modified [(99m)Tc]Tc-DT1 Mimics: A Comparative Study in NTS(1)R-Positive Models
por: Kanellopoulos, Panagiotis, et al.
Publicado: (2023)

Key-Protease Inhibition Regimens Promote Tumor Targeting of Neurotensin Radioligands
por: Kanellopoulos, Panagiotis, et al.
Publicado: (2020)

(66)Ga-PET-imaging of GRPR-expression in prostate cancer: production and characterization of [(66)Ga]Ga-NOTA-PEG(2)-RM26
por: Rinne, Sara S., et al.
Publicado: (2021)

The GRPR Antagonist [(99m)Tc]Tc-maSSS-PEG(2)-RM26 towards Phase I Clinical Trial: Kit Preparation, Characterization and Toxicity
por: Abouzayed, Ayman, et al.
Publicado: (2023)

Localization of (99m)Tc-GRP Analogs in GRPR-Expressing Tumors: Effects of Peptide Length and Neprilysin Inhibition on Biological Responses
por: Kaloudi, Aikaterini, et al.
Publicado: (2019)

Comparing Gly(11)/dAla(11)-Replacement vs. the in-Situ Neprilysin-Inhibition Approach on the Tumor-targeting Efficacy of the (111)In-SB3/(111)In-SB4 Radiotracer Pair
por: Lymperis, Emmanouil, et al.
Publicado: (2019)

Bispecific GRPR-Antagonistic Anti-PSMA/GRPR Heterodimer for PET and SPECT Diagnostic Imaging of Prostate Cancer
por: Mitran, Bogdan, et al.
Publicado: (2019)

One Step Closer to Clinical Translation: Enhanced Tumor Targeting of [(99m)Tc]Tc-DB4 and [(111)In]In-SG4 in Mice Treated with Entresto
por: Kanellopoulos, Panagiotis, et al.
Publicado: (2020)

Structures of human gastrin-releasing peptide receptors bound to antagonist and agonist for cancer and itch therapy
por: Peng, Shuman, et al.
Publicado: (2023)

Targeting prostate cancer with radiolabelled bombesins
por: Maina, Theodosia, et al.
Publicado: (2006)

NeoBOMB1, a GRPR-Antagonist for Breast Cancer Theragnostics: First Results of a Preclinical Study with [(67)Ga]NeoBOMB1 in T-47D Cells and Tumor-Bearing Mice
por: Kaloudi, Aikaterini, et al.
Publicado: (2017)

A Theranostic Approach to Target Gastrin in Pancreatic Cancer
por: Banerjee, Sulagna, et al.
Publicado: (2018)

Preclinical Characterisation of PSMA/GRPR-Targeting Heterodimer [(68)Ga]Ga-BQ7812 for PET Diagnostic Imaging of Prostate Cancer: A Step towards Clinical Translation
por: Lundmark, Fanny, et al.
Publicado: (2023)

Gastrin-Releasing Peptide and Glucose Metabolism Following Pancreatitis
por: Pendharkar, Sayali A., et al.
Publicado: (2017)

Gastrin-Releasing Peptide (GRP) Stimulates Osteoclastogenesis in Periodontitis
por: Choi, YunJeong, et al.
Publicado: (2020)

Analgesic effect of gastrin-releasing peptide in the dorsal horn
por: Saeki, Ayano, et al.
Publicado: (2022)

(177)Lu-labeled PSMA targeting therapeutic with optimized linker for treatment of disseminated prostate cancer; evaluation of biodistribution and dosimetry
por: Abouzayed, Ayman, et al.
Publicado: (2023)

HER3 PET Imaging: (68)Ga-Labeled Affibody Molecules Provide Superior HER3 Contrast to (89)Zr-Labeled Antibody and Antibody-Fragment-Based Tracers
por: Rinne, Sara S., et al.
Publicado: (2021)

Gastrin-releasing Peptide Receptor Imaging in Breast Cancer Using the Receptor Antagonist (68)Ga-RM2 And PET
por: Stoykow, Christian, et al.
Publicado: (2016)

First in-human radiation dosimetry of the gastrin-releasing peptide (GRP) receptor antagonist (68)Ga-NODAGA-MJ9
por: Gnesin, Silvano, et al.
Publicado: (2018)

Gastrin-releasing peptide, substance P and cytokines in rheumatoid arthritis
por: Green, Paul G
Publicado: (2005)

How Gastrin-Releasing Peptide Opens the Spinal Gate for Itch
por: Pagani, Martina, et al.
Publicado: (2019)

Nanostrategies for Therapeutic and Diagnostic Targeting of Gastrin-Releasing Peptide Receptor
por: Rurarz, Beata Paulina, et al.
Publicado: (2023)

Comparative biodistribution of 12 (111)In-labelled gastrin/CCK2 receptor-targeting peptides
por: Laverman, Peter, et al.
Publicado: (2011)

Heterodimeric Radiotracer Targeting PSMA and GRPR for Imaging of Prostate Cancer—Optimization of the Affinity towards PSMA by Linker Modification in Murine Model
por: Lundmark, Fanny, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_p644e8689sjqulh9kjdurnkc2o